Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Protagonist Therapeutics Inc’s stock clocked out at $82.27, down -2.27% from its previous closing price of $84.18. In other words, the price has decreased by -$2.27 from its previous closing price. On the day, 0.73 million shares were traded. PTGX stock price reached its highest trading level at $85.0 during the session, while it also had its lowest trading level at $81.67.
Ratios:
To gain a deeper understanding of PTGX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.93 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 80.73. For the most recent quarter (mrq), Quick Ratio is recorded 13.05 and its Current Ratio is at 13.05. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, Barclays on September 17, 2025, initiated with a Overweight rating and assigned the stock a target price of $72.
On September 12, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $73.
On June 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $72.Citigroup initiated its Buy rating on June 17, 2025, with a $72 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 17 ’25 when MOLINA ARTURO MD sold 2,712 shares for $84.77 per share. The transaction valued at 229,896 led to the insider holds 81,180 shares of the business.
Waddill William D. sold 12,000 shares of PTGX for $979,480 on Oct 10 ’25. The Director now owns 5,130 shares after completing the transaction at $81.62 per share. On Oct 10 ’25, another insider, WILLIAM WADDILL, who serves as the Director of the company, bought 12,000 shares for $67.04 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTGX now has a Market Capitalization of 5143163392 and an Enterprise Value of 4577796096. As of this moment, Protagonist’s Price-to-Earnings (P/E) ratio for their current fiscal year is 129.89, and their Forward P/E ratio for the next fiscal year is 96.84. For the stock, the TTM Price-to-Sale (P/S) ratio is 24.58 while its Price-to-Book (P/B) ratio in mrq is 7.96. Its current Enterprise Value per Revenue stands at 21.881 whereas that against EBITDA is 228.547.
Stock Price History:
The Beta on a monthly basis for PTGX is 2.27, which has changed by 1.2376397 over the last 52 weeks, in comparison to a change of 0.16623151 over the same period for the S&P500. Over the past 52 weeks, PTGX has reached a high of $96.54, while it has fallen to a 52-week low of $33.70. The 50-Day Moving Average of the stock is -3.51%, while the 200-Day Moving Average is calculated to be 32.08%.
Shares Statistics:
It appears that PTGX traded 1.13M shares on average per day over the past three months and 638350 shares per day over the past ten days. A total of 62.45M shares are outstanding, with a floating share count of 59.09M. Insiders hold about 5.47% of the company’s shares, while institutions hold 110.59% stake in the company. Shares short for PTGX as of 1765756800 were 6539025 with a Short Ratio of 5.81, compared to 1763078400 on 5582326. Therefore, it implies a Short% of Shares Outstanding of 6539025 and a Short% of Float of 12.529999.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 9.0 analysts currently analyzing and rating the stock of Protagonist Therapeutics Inc (PTGX).The consensus estimate for the next quarter is -$0.43, with high estimates of $0.06 and low estimates of -$0.75.
Analysts are recommending an EPS of between -$1.26 and -$2.33 for the fiscal current year, implying an average EPS of -$1.87. EPS for the following year is $1.06, with 9.0 analysts recommending between $5.04 and -$2.36.
Revenue Estimates
A total of 11 analysts have provided revenue estimates for PTGX’s current fiscal year. The highest revenue estimate was $258.9M, while the lowest revenue estimate was $38.58M, resulting in an average revenue estimate of $66.81M. In the same quarter a year ago, actual revenue was $434.43MBased on 10 analysts’ estimates, the company’s revenue will be $274.27M in the next fiscal year. The high estimate is $525M and the low estimate is $20M.
